Synchronous Hürthle cell and medullary thyroid carcinomas

Abstract

Hürthle cell carcinoma (HCC) and medullary thyroid carcinomas (MTC) are uncommon histological subtypes of thyroid cancers, each accounting for around 3% of all thyroid cancers. A septuagenarian woman with a history of multiple primary cancer diagnoses presented with a growing left-sided neck lump. A diagnostic left thyroid lobectomy was performed, and pathological examination found two separate malignant foci: one HCC and an MTC. The patient developed left-sided HCC nodal metastasis, and following several multidisciplinary team discussions, a right completion lobectomy with left lateral neck dissection was performed, revealing further intrathyroidal MTC and extranodal extension of HCC. We present this as the first reported case of a collision tumour of HCC and MTC, and review the available literature regarding collision tumours and their management.

Thyroid collision tumour with pulmonary metastases treated effectively with nedaplatin and paclitaxel chemotherapy: A case report

“…Therefore, it is difficult to determine whether standard treatment options, metastasis rates and prognosis for collision tumours are similar to those for single tumors. 21 , 22 The consensus of opinion is that both entities in collision tumours should be considered as separate primary tumours, with different treatment options for different subtypes. For example, with respect to collision tumours with tissue components, such as OC, complete excision of the gland is required with simultaneous lymph node dissection if necessary.…”

Thyroid Collision Tumors: The Presence of the Medullary Thyroid Carcinoma Component Negatively Influences the Prognosis

“…The most frequent association encountered in TCTs is the synchronous presence of medullary thyroid carcinoma (MTC) and papillary thyroid carcinoma (PTC) components [1,11]. Still, other combinations have been reported in the literature, including squamous cell carcinoma (SCC) and PTC, PTC and follicular thyroid carcinoma (FTC), Diagnostics 2023, 13, 285 2 of 16 Hurthle cell thyroid carcinoma (HTC) associated with PTC and poorly differentiated thyroid carcinoma (PDTC), and HTC associated with MTC [12][13][14][15].…”